UK critical care monitoring and diagnostics equipment specialist Sphere Medical, has launched its next generation CE-marked Proxima™ system.
Sphere Medical’s unique new-design Proxima bedside blood gas analyser (BGA) now features glucose analysis and other calculated parameters, such as P/F ratio and temperature corrected gases. The ability to monitor blood gases and measure blood glucose frequently and easily, directly by the patient, can enable earlier interventions and closer patient management, which the company points out is vital in fast-changing critical situations.
As its name hints, Proxima is always connected to the patient via their arterial line and is ready to go instantly. Since results are also delivered without the caregiver leaving the patient’s bedside, this significantly reduces time to result compared to conventional benchtop analysers. The system can travel with the patient on their pathway through the hospital. This is possible since the Proxima sensor contains an array of proven biosensor technology on a silicon chip, each a miniaturised version of the electrochemical sensors used in a traditional blood gas analyser.
This next generation Proxima system now also includes a medical grade tablet monitor with an intuitive touchscreen user interface. All results are reported to the monitor and seamlessly transferred directly into laboratory information systems and electronic patient records, a key requirement for the successful implementation of point-of-care (POC) testing.
The addition of glucose to the new Proxima’s analyte panel is significant as glucose measurements play a key part in the care of critically ill patients. Both hyperglycaemia and hypoglycaemia are associated with increased morbidity and mortality in intensive care unit (ICU) patients. Keeping patients in normal glycaemic range is difficult with current systems. The ability to regularly monitor arterial blood glucose using Proxima will support closer clinical management for improved glycaemic control.
Professor of Anaesthesia and Intensive Care Medicine, Mike Grocott, University of Southampton, also commented, “The recent time and motion study we conducted at University Hospital Southampton clearly highlighted the workflow benefits of using Proxima on critically ill, unstable patients. We look forward to the launch of the new Proxima and the opportunity to use this device on a larger patient group within the ICU.”
“Proxima is already redefining how arterial blood gas testing is carried out in critically ill patients through its use for the close monitoring of patients in the UK, Germany and Belgium,” said Dr Wolfgang Rencken, Chief Executive Officer, Sphere Medical. “Based on clinical feedback, we have launched our next generation Proxima which is now even better placed to support rapid and frequent measurements of blood gases, electrolytes and metabolites without blood loss. The addition of glucose to the analyte panel is the most significant new parameter, enabling better glycaemic control in the critically ill.”
Source: Sphere Medical Ltd.